192(top 100%)
PR articles
15.9K(top 1%)
PR citations
62(top 100%)
PR h-index
66(top 100%)
h-index
216
documents
19.4K
doc citations
2.0K
citing journals
100
times ranked

Publications

193 PR articles • 16,329 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study
Pharmacogenomics Journal, 2023, 23, 119-126
2.86Citations (PDF)
2Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment
ELife, 2023, 12,
1.67Citations (PDF)
3Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom
Translational Psychiatry, 2022, 12,
5.511Citations (PDF)
4Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents
Schizophrenia, 2022, 8,
3.23Citations (PDF)
5Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice
Behavioural Brain Research, 2022, 432, 113964
2.33Citations (PDF)
6Schizophrenia‐associated gene dysbindin‐1 and tardive dyskinesia
Drug Development Research, 2021, 82, 678-684
3.57Citations (PDF)
7Contrasting Typical and Atypical Antipsychotic Drugs
Focus (American Psychiatric Publishing), 2021, 19, 3-13
1.129Citations (PDF)
8An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system
Science Advances, 2021, 7,
11.015Citations (PDF)
9Depolarizing GABA <sub>A</sub> current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia
Science Advances, 2021, 7,
11.025Citations (PDF)
10The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia
Schizophrenia Research, 2020, 215, 314-321
2.47Citations (PDF)
11Liver Enzyme <i>CYP2D6</i> Gene and Tardive Dyskinesia
Pharmacogenomics, 2020, 21, 1065-1072
1.68Citations (PDF)
12M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
Schizophrenia Bulletin, 2020, 46, S202-S202
4.30Citations (PDF)
13Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
Frontiers in Pharmacology, 2020, 11,
4.015Citations (PDF)
14Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action
Pharmacology Biochemistry and Behavior, 2020, 190, 172872
2.420Citations (PDF)
15Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
Journal of Clinical Psychopharmacology, 2020, 40, 240-249
1.841Citations (PDF)
16Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans
Schizophrenia Research, 2019, 212, 204-212
2.419Citations (PDF)
17The Role of Dopamine D<sub>3</sub> Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens
Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 517-525
3.327Citations (PDF)
18New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109659
4.09Citations (PDF)
19Association of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
Frontiers in Psychiatry, 2019, 10,
2.616Citations (PDF)
20Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma
Journal of Neuroscience, 2019, 39, 1982-1993
3.790Citations (PDF)
21The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice
Behavioural Brain Research, 2019, 361, 139-150
2.324Citations (PDF)
22A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs
Pharmacogenomics Journal, 2019, 20, 260-270
2.818Citations (PDF)
23Hippocampal GABA A antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats
Behavioural Brain Research, 2018, 342, 11-18
2.37Citations (PDF)
24Dissecting the Functional Consequences of De Novo DNA Methylation Dynamics in Human Motor Neuron Differentiation and Physiology
Cell Stem Cell, 2018, 22, 559-574.e9
16.877Citations (PDF)
25Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes
Schizophrenia Research, 2018, 192, 194-204
2.475Citations (PDF)
26Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain
World Journal of Biological Psychiatry, 2018, 19, S97-S105
4.413Citations (PDF)
27F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS
Schizophrenia Bulletin, 2018, 44, S218-S218
4.30Citations (PDF)
28Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis
Frontiers in Pharmacology, 2018, 9,
4.020Citations (PDF)
29T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2
Schizophrenia Bulletin, 2018, 44, S115-S115
4.30Citations (PDF)
305-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA
Psychopharmacology, 2018, 235, 2795-2808
2.927Citations (PDF)
31Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials
Schizophrenia Research, 2018, 199, 203-213
2.419Citations (PDF)
32Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia
Neuroscience Letters, 2018, 686, 17-22
1.97Citations (PDF)
33TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia
Neuropsychopharmacology, 2018, 43, 2468-2477
5.514Citations (PDF)
34A within‐subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery
CNS Neuroscience and Therapeutics, 2018, 24, 641-651
5.27Citations (PDF)
35Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain
Journal of Neural Transmission, 2018, 126, 27-33
3.514Citations (PDF)
36Association study between the neurexin‐1 gene and tardive dyskinesia
Human Psychopharmacology, 2017, 32,
1.89Citations (PDF)
37Dopamine D<sub>4</sub> receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia
Journal of Psychopharmacology, 2017, 31, 442-452
5.231Citations (PDF)
38Neurochemical arguments for the use of dopamine D 4 receptor stimulation to improve cognitive impairment associated with schizophrenia
Pharmacology Biochemistry and Behavior, 2017, 157, 16-23
2.422Citations (PDF)
39Replication of rs300774, a genetic biomarker near ACP1, associated with suicide attempts in patients with schizophrenia: Relation to brain cholesterol biosynthesis
Journal of Psychiatric Research, 2017, 94, 54-61
3.020Citations (PDF)
40RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia
Behavioural Brain Research, 2017, 332, 180-199
2.324Citations (PDF)
415-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Neuropsychopharmacology, 2017, 42, 2163-2177
5.549Citations (PDF)
42Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats
Journal of Psychopharmacology, 2017, 31, 1588-1604
5.214Citations (PDF)
43Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice
Pharmacology Biochemistry and Behavior, 2017, 159, 6-11
2.425Citations (PDF)
44Reduced Glutamatergic Currents and Dendritic Branching of Layer 5 Pyramidal Cells Contribute to Medial Prefrontal Cortex Deactivation in a Rat Model of Neuropathic Pain
Frontiers in Cellular Neuroscience, 2016, 10,
3.590Citations (PDF)
45Genetic association analysis of N‐methyl‐<scp>d</scp>‐aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine
Human Psychopharmacology, 2016, 31, 121-134
1.819Citations (PDF)
46Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U
Biological Psychiatry, 2016, 80, 878-887
5.527Citations (PDF)
47Preliminary Evidence for Association of Genome-Wide Significant <i>DRD2</i> Schizophrenia Risk Variant with Clozapine Response
Pharmacogenomics, 2016, 17, 103-109
1.638Citations (PDF)
48GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice
Behavioural Brain Research, 2016, 299, 105-110
2.345Citations (PDF)
49Association of orexin receptor polymorphisms with antipsychotic-induced weight gain
World Journal of Biological Psychiatry, 2016, 17, 221-229
4.425Citations (PDF)
50Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition
Behavioural Brain Research, 2016, 301, 204-212
2.324Citations (PDF)
51Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism
Behavioural Brain Research, 2016, 301, 132-141
2.315Citations (PDF)
52Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus
Neuropharmacology, 2016, 100, 90-97
4.438Citations (PDF)
53The brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia
Bipolar Disorders, 2015, 17, 528-535
2.560Citations (PDF)
54Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis
Angewandte Chemie, 2015, 127, 7004-7008
1.46Citations (PDF)
55A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells
PLoS ONE, 2015, 10, e0121707
2.46Citations (PDF)
56Pharmacotherapy of cognition in schizophrenia
Current Opinion in Behavioral Sciences, 2015, 4, 115-121
3.126Citations (PDF)
57Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis
Angewandte Chemie - International Edition, 2015, 54, 6900-6904
14.429Citations (PDF)
58Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats
Behavioural Brain Research, 2015, 285, 165-175
2.328Citations (PDF)
59Decreased serotonin2C receptor responses in male patients with schizophrenia
Psychiatry Research, 2015, 226, 308-315
3.35Citations (PDF)
60Identification of the role of bone morphogenetic protein (<scp>BMP</scp>) and transforming growth factor‐β (TGF‐β) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells <i>in vitro</i>
Journal of Neurochemistry, 2015, 132, 418-428
3.912Citations (PDF)
61Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement
Pharmacology Biochemistry and Behavior, 2015, 138, 49-57
2.427Citations (PDF)
62Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice
Psychopharmacology, 2015, 233, 649-660
2.929Citations (PDF)
63A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
Journal of Clinical Psychiatry, 2015, 76, 1085-1090
2.8106Citations (PDF)
64The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens
Psychopharmacology, 2014, 231, 4541-4551
2.948Citations (PDF)
65A genetic locus in 7p12.2 associated with treatment resistant schizophrenia
Schizophrenia Research, 2014, 159, 333-339
2.426Citations (PDF)
66Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5‐<scp>HT</scp>)<sub>2A</sub> and <scp>DA</scp> D<sub>2</sub> antagonism and 5‐<scp>HT</scp><sub>1A</sub> partial agonism
Journal of Neurochemistry, 2014, 128, 938-949
3.972Citations (PDF)
67Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt
Neuropsychopharmacology, 2014, 39, 1902-1913
5.563Citations (PDF)
68Schizophrenia and Suicide: Treatment Optimization
Current Treatment Options in Psychiatry, 2014, 1, 149-162
2.22Citations (PDF)
69Language-dependent performance on the letter fluency task in patients with schizophrenia
Schizophrenia Research, 2014, 152, 421-429
2.411Citations (PDF)
70No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain
Psychiatry Research, 2014, 219, 255-260
3.314Citations (PDF)
71Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice
Neuropsychopharmacology, 2014, 40, 1141-1150
5.531Citations (PDF)
72The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia
Current Pharmaceutical Design, 2014, 20, 5104-5114
2.4155Citations (PDF)
73Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia
Journal of Psychiatric Research, 2013, 47, 1760-1765
3.060Citations (PDF)
74D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats
Behavioural Brain Research, 2013, 238, 36-43
2.339Citations (PDF)
75Update on Typical and Atypical Antipsychotic Drugs
Annual Review of Medicine, 2013, 64, 393-406
19.5376Citations (PDF)
76Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
International Journal of Neuropsychopharmacology, 2013, 16, 2181-2194
2.8111Citations (PDF)
77Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
Journal of Clinical Investigation, 2013, 123, 4986-4991
10.7106Citations (PDF)
78A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia
Neuropsychopharmacology, 2013, 39, 1347-1354
5.529Citations (PDF)
79The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release
Psychopharmacology, 2013, 231, 2199-2210
2.926Citations (PDF)
80Mechanisms of Clozapine†-Induced Agranulocytosis
Drug Safety, 2012, 7, 17-25
2.931Citations (PDF)
81Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist
Neuropsychopharmacology, 2012, 37, 2175-2183
5.542Citations (PDF)
82The Novel Antipsychotic Drug Lurasidone Enhances <i>N</i>-Methyl-d-aspartate Receptor-Mediated Synaptic Responses
Molecular Pharmacology, 2012, 81, 113-119
2.736Citations (PDF)
835-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux
NeuroReport, 2012, 23, 436-440
1.544Citations (PDF)
84Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
Schizophrenia Research, 2012, 141, 144-152
2.495Citations (PDF)
85Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia
Psychiatry Research, 2012, 198, 202-206
3.324Citations (PDF)
86Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 62-75
4.036Citations (PDF)
87Clozapine
Clinical Schizophrenia and Related Psychoses, 2012, 6, 134-144
1.0207Citations (PDF)
88The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response
Schizophrenia Research, 2011, 132, 121-124
2.426Citations (PDF)
895-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine efflux—Studied in 5-HT2A and 5-HT2C genetic mutant mice
European Journal of Pharmacology, 2011, 652, 40-45
4.423Citations (PDF)
90The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
Psychopharmacology, 2011, 213, 289-305
2.9114Citations (PDF)
91Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats
Psychopharmacology, 2011, 217, 13-24
2.961Citations (PDF)
92Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
American Journal of Psychiatry, 2011, 168, 957-967
10.4253Citations (PDF)
93A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients
Journal of Clinical Psychiatry, 2011, 72, 1602-1610
2.841Citations (PDF)
94Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response
Human Psychopharmacology, 2010, 25, 582-585
1.817Citations (PDF)
95Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data
Schizophrenia Research, 2010, 122, 38-42
2.4198Citations (PDF)
96A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia
Psychiatry Research, 2010, 177, 286-293
3.325Citations (PDF)
97Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex
Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 948-955
3.321Citations (PDF)
98A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia
PLoS Genetics, 2009, 5, e1000373
3.3394Citations (PDF)
99Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Psychopharmacology, 2009, 205, 119-128
2.9260Citations (PDF)
100Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function
Psychiatry Research, 2009, 169, 178-179
3.342Citations (PDF)
101Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
Neuropsychopharmacology, 2009, 35, 881-892
5.5300Citations (PDF)
102Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine
European Journal of Pharmacology, 2008, 596, 89-97
4.421Citations (PDF)
103Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder
Schizophrenia Research, 2008, 106, 258-264
2.434Citations (PDF)
104Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?
Behavioural Brain Research, 2008, 195, 98-102
2.3163Citations (PDF)
105Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacological Reviews, 2008, 60, 358-403
16.0222Citations (PDF)
106Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus
Neuropsychopharmacology, 2008, 33, 2934-2945
5.547Citations (PDF)
107In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
Progress in Brain Research, 2008, , 177-197
3.0222Citations (PDF)
108Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
Journal of Clinical Psychopharmacology, 2008, 28, 392-400
1.892Citations (PDF)
109A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia
Journal of Clinical Psychiatry, 2008, 69, 274-285
2.8154Citations (PDF)
110WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity
Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 486-496
3.3145Citations (PDF)
111Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Archives of General Psychiatry, 2007, 64, 633
13.61,007Citations (PDF)
112A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects
Schizophrenia Research, 2007, 89, 211-224
2.4132Citations (PDF)
1135-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus
Brain Research, 2007, 1134, 70-78
2.559Citations (PDF)
114Aripiprazole for Treatment-Resistant Schizophrenia
Journal of Clinical Psychiatry, 2007, 68, 213-223
2.8114Citations (PDF)
115Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know
CNS Spectrums, 2006, 11, 14-24
0.641Citations (PDF)
116Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex
Brain Research, 2006, 1099, 44-55
2.536Citations (PDF)
117Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial
Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 115-120
0.10Citations (PDF)
118Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
American Journal of Psychiatry, 2006, 163, 600-610
10.4827Citations (PDF)
119The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
International Journal of Neuropsychopharmacology, 2005, 8, 153-156
2.828Citations (PDF)
120ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
Psychopharmacology, 2005, 183, 144-153
2.958Citations (PDF)
121Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations
Psychopharmacology, 2005, 181, 179-187
2.992Citations (PDF)
122A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
International Journal of Neuropsychopharmacology, 2005, 8, 457-472
2.8552Citations (PDF)
123A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine
Journal of Clinical Psychiatry, 2005, 66, 63-72
2.8173Citations (PDF)
124Suicide in Schizophrenia, Clozapine, and Adoption of Evidence-Based Medicine
Journal of Clinical Psychiatry, 2005, 66, 530-533
2.856Citations (PDF)
125Serotonin 1A Receptors in Memory Function
American Journal of Psychiatry, 2004, 161, 1505-1505
10.426Citations (PDF)
126Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment
CNS Spectrums, 2004, 9, 15-24
0.653Citations (PDF)
127Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder
American Journal of Psychiatry, 2004, 161, 975-984
10.4339Citations (PDF)
128Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain
European Journal of Pharmacology, 2004, 493, 75-83
4.4186Citations (PDF)
129Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism
Brain Research, 2004, 1023, 54-63
2.583Citations (PDF)
130Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease
Neuropsychopharmacology, 2003, 12, 39-45
5.533Citations (PDF)
131Clozapine-induced weight gain predicts improvement in psychopathology
Schizophrenia Research, 2003, 59, 19-27
2.4127Citations (PDF)
132Serotonin receptors : their key role in drugs to treat schizophrenia
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1159-1172
4.0700Citations (PDF)
133H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
Neuropsychopharmacology, 2003, 28, 519-526
5.5741Citations (PDF)
134Clozapine Treatment for Suicidality in Schizophrenia&lt;subtitle&gt;International Suicide Prevention Trial (InterSePT)&lt;/subtitle&gt;
Archives of General Psychiatry, 2003, 60, 82
13.61,320Citations (PDF)
135Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes
CNS Spectrums, 2003, 8, 16-18
0.68Citations (PDF)
136Reducing the Risk for Suicide in Schizophrenia and Affective Disorders
Journal of Clinical Psychiatry, 2003, 64, 1122-1129
2.840Citations (PDF)
1375-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex
Brain Research, 2002, 939, 34-42
2.550Citations (PDF)
1385-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner
Brain Research, 2002, 947, 157-165
2.5125Citations (PDF)
139Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism
Brain Research, 2002, 956, 349-357
2.5206Citations (PDF)
140SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens
Neuropsychopharmacology, 2002, 27, 430-441
5.572Citations (PDF)
141Commentary on "Clinical studies on the mechanism of action of clozapine; the dopamine–serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18–S27
Psychopharmacology, 2002, 163, 1-3
2.937Citations (PDF)
142The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
Biological Psychiatry, 2001, 49, 861-868
5.5153Citations (PDF)
1435‐HT<sub>2A</sub> and D<sub>2</sub> receptor blockade increases cortical DA release via 5‐HT<sub>1A</sub> receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release
Journal of Neurochemistry, 2001, 76, 1521-1531
3.9505Citations (PDF)
144Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment
American Journal of Psychiatry, 2001, 158, 1722-1725
10.4207Citations (PDF)
145Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum
Neuropsychopharmacology, 2001, 26, 325-339
5.5225Citations (PDF)
146Treatment of Suicidality in Schizophrenia
Annals of the New York Academy of Sciences, 2001, 932, 44-60
4.1110Citations (PDF)
147Effect of Adjunctive Treatment With Serotonin-1A Agonist Tandospirone on Memory Functions in Schizophrenia
Journal of Clinical Psychopharmacology, 2000, 20, 386-388
1.861Citations (PDF)
148Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation
Psychopharmacology, 1999, 144, 255-263
2.928Citations (PDF)
149Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia
Neuropsychopharmacology, 1999, 21, 17-27
5.5148Citations (PDF)
150Brain Noradrenergic Receptors in Major Depression and Schizophrenia
Neuropsychopharmacology, 1999, 21, 69-81
5.576Citations (PDF)
151The Role of Serotonin in Antipsychotic Drug Action
Neuropsychopharmacology, 1999, 21, 106S-115S
5.5619Citations (PDF)
152Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S90-S98
2.8140Citations (PDF)
153Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens
European Journal of Pharmacology, 1998, 351, 163-171
4.483Citations (PDF)
154Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients
Neuropsychopharmacology, 1998, 19, 123-132
5.5226Citations (PDF)
155The Evolution of Treatment Resistance: Biologic Implications
Journal of Clinical Psychopharmacology, 1998, 18, 5S-11S
1.828Citations (PDF)
156Treatment-Resistant Schizophrenia - The Role of Clozapine
Current Medical Research and Opinion, 1997, 14, 1-20
2.2449Citations (PDF)
157Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs
Psychiatry Research, 1997, 66, 1-11
3.3334Citations (PDF)
158Serotonin Receptors in Suicide Victims with Major Depression
Neuropsychopharmacology, 1997, 16, 162-173
5.5145Citations (PDF)
159The Effect of Streptozotocin-Induced Diabetes on Dopamine2, Serotonin1A and Serotonin2A Receptors in the Rat Brain
Neuropsychopharmacology, 1997, 16, 183-190
5.537Citations (PDF)
160Fluoxetine, but not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-Mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder
Neuropsychopharmacology, 1997, 17, 1-11
5.563Citations (PDF)
161Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers
Psychiatry Research, 1996, 64, 147-159
3.320Citations (PDF)
162Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review
British Journal of Psychiatry, 1996, 168, 23-31
1.963Citations (PDF)
163Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia
Brain Research, 1996, 708, 209-214
2.5158Citations (PDF)
164Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT<sub>6</sub> Serotonin Receptor
Journal of Neurochemistry, 1996, 66, 47-56
3.9343Citations (PDF)
165Dr. Meltzer and Mr. Cola Reply
American Journal of Psychiatry, 1995, 152, 153-154
10.4136Citations (PDF)
166Association study between the dopamine D4 receptor gene and schizophrenia
American Journal of Medical Genetics Part A, 1995, 60, 452-455
0.552Citations (PDF)
167Association study of dopamine D3 receptor gene and schizophrenia
American Journal of Medical Genetics Part A, 1995, 60, 558-562
0.555Citations (PDF)
168Plasma Clozapine and Desmethylclozapine Levels in Clozapine-Induced Agranulocytosis
Neuropsychopharmacology, 1994, 11, 45-47
5.534Citations (PDF)
169Effect of Clozapine Treatment on Serotonin-2—Receptor Binding in the Blood Platelets of Schizophrenic Patients
Neuropsychopharmacology, 1994, 10, 109-114
5.513Citations (PDF)
170The Effect of Apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and Placebo on Smooth Pursuit Gain and Corrective Saccades in Normal Subjects
Neuropsychopharmacology, 1994, 11, 49-62
5.514Citations (PDF)
171N‐desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis
British Journal of Haematology, 1994, 86, 555-561
2.490Citations (PDF)
172Blunted oral body temperature response to MK-212 in cocaine addicts
Drug and Alcohol Dependence, 1994, 35, 217-222
3.020Citations (PDF)
173Recent advances in the pharmacotherapy of schxzophrenia
Acta Psychiatrica Scandinavica, 1994, 90, 95-101
4.458Citations (PDF)
174Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
Biological Psychiatry, 1993, 34, 702-712
5.5372Citations (PDF)
175Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia
Biological Psychiatry, 1992, 31, 460-470
5.518Citations (PDF)
176The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo
Brain Research, 1992, 574, 98-104
2.534Citations (PDF)
177Amperozide, a Novel Antipsychotic Drug, Inhibits the Ability of d-Amphetamine to Increase Dopamine Release In Vivo in Rat Striatum and Nucleus Accumbens
Journal of Neurochemistry, 1992, 58, 2285-2291
3.956Citations (PDF)
178Effect of 3,4-Methylenedioxymethamphetamine on 3,4-Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens
Journal of Neurochemistry, 1990, 54, 1062-1067
3.951Citations (PDF)
179Serotonergic Dysfunction in Depression
British Journal of Psychiatry, 1989, 155, 25-31
1.9201Citations (PDF)
180Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses
Pharmacology Biochemistry and Behavior, 1989, 33, 781-785
2.440Citations (PDF)
181Basic biology of clozapine: electrophysiological and neuroendocrinological studies
Psychopharmacology, 1989, 99, S13-S17
2.938Citations (PDF)
182Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia
Psychopharmacology, 1989, 99, S18-S27
2.9553Citations (PDF)
183Clozapine: New research on efficacy and mechanism of action
European Archives of Psychiatry and Neurological Sciences, 1989, 238, 332-339
0.896Citations (PDF)
184Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex
Life Sciences, 1989, 45, 1397-1406
4.783Citations (PDF)
185Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs
Acta Psychiatrica Scandinavica, 1989, 80, 24-29
4.431Citations (PDF)
186Duration of a Clozapine Trial in Neuroleptic-Resistant Schizophrenia
Archives of General Psychiatry, 1989, 46, 672
13.669Citations (PDF)
187Novel approaches to the pharmacotherapy of schizophrenia
Drug Development Research, 1986, 9, 23-40
3.535Citations (PDF)
188Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin2Receptors in Rat Cerebral Cortex
Journal of Neurochemistry, 1986, 46, 191-197
3.985Citations (PDF)
189Descriptive studies of H-reflex recovery curves in psychiatric patients
Psychological Medicine, 1980, 10, 541-548
4.223Citations (PDF)
190Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotypes behavior and ataxia in rats
European Journal of Pharmacology, 1979, 59, 169-179
4.4231Citations (PDF)
191Serum Creatine Phosphokinase Activity in Acute Psychosis
British Journal of Psychiatry, 1973, 122, 369-369
1.90Citations (PDF)
192Muscle Abnormalities in Acute Psychoses
Archives of General Psychiatry, 1970, 23, 481
13.661Citations (PDF)
193Awareness of illness moderates self-assessment of psychotic symptoms
Australian and New Zealand Journal of Psychiatry, 0, , 000486742110574
3.43Citations (PDF)